We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-1.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
-$253M
Cap. Flow
-$97.3M
Cap. Flow %
-8.43%
Top 10 Hldgs %
65.98%
Holding
89
New
12
Increased
29
Reduced
25
Closed
19
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.2 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
1 year

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$63.1M
2
NTRA icon
Natera
NTRA
+$45.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.6M
4
ILMN icon
Illumina
ILMN
+$14.6M
5
MCRB icon
Seres Therapeutics
MCRB
+$9.91M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$67.4M
2
AVTR icon
Avantor
AVTR
+$28M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$21.6M
4
ARGX icon
argenx
ARGX
+$16.9M
5
FATE icon
Fate Therapeutics
FATE
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 72.39%
2 Miscellaneous 27.61%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VRDN icon
26
Viridian Therapeutics
VRDN
$2.19B
$9.81M 0.85%
478,387
+32,795
+7% +$590K
2021 Q3
4 quarters
AMRX icon
27
Amneal Pharmaceuticals
AMRX
$6.63B
$9.48M 0.82%
4,690,812
-803,468
-15% -$2.25M
2020 Q2
9 quarters
XENE icon
28
Xenon Pharmaceuticals
XENE
$3.26B
$9.37M 0.81%
259,612
-206,299
-44% -$7.42M
2021 Q4
3 quarters
GH icon
29
Guardant Health
GH
$21.4B
$9.23M 0.8%
171,481
-234,894
-58% -$12.1M
2021 Q1
6 quarters
IONS icon
30
Ionis Pharmaceuticals
IONS
$7.19B
$8.93M 0.77%
201,833
+115,522
+134% +$4.87M
2021 Q2
5 quarters
XBI icon
31
State Street SPDR S&P Biotech ETF
XBI
$9.57B
$7.93M 0.69%
100,000
-256,067
-72% -$21.6M
2022 Q2
1 quarter
LQDA icon
32
Liquidia Corp
LQDA
$3.02B
$7.62M 0.66%
1,401,443
-698,265
-33% -$3.92M
2021 Q1
6 quarters
XBI icon
33
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.57B
$7.14M 0.62%
90,000
-169,800
-65% -$14.3M
2022 Q2
1 quarter
TARO icon
34
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$6.7M 0.58%
223,383
+2,993
+1% +$103K
2019 Q4
11 quarters
GOSS icon
35
Gossamer Bio
GOSS
$54.7M
$6.57M 0.57%
6,855
+1,001
+17% +$994K
2021 Q3
4 quarters
PLRX icon
36
Pliant Therapeutics
PLRX
$55.9M
$6.14M 0.53%
+294,103
New +$5.63M
2022 Q3
0 quarters
MRUS icon
37
DELISTED
Merus
MRUS
$5.54M 0.48%
276,673
-11,133
-4% -$266K
2021 Q4
3 quarters
MRK icon
38
CALL
Merck
MRK
$363B
$4.19M 0.36%
48,700
– –
2021 Q2
5 quarters
MRVI icon
39
Maravai LifeSciences
MRVI
$1.03B
$4.08M 0.35%
160,000
-265,364
-62% -$6.66M
2022 Q2
1 quarter
AFMD icon
40
DELISTED
Affimed
AFMD
$3.89M 0.34%
188,800
+75,724
+67% +$2.1M
2022 Q2
1 quarter
AERI
41
DELISTED
Aerie Pharmaceuticals
AERI
$3.88M 0.34%
+256,289
New +$2.98M
2022 Q3
0 quarters
PBYI icon
42
Puma Biotechnology
PBYI
$516M
$3.57M 0.31%
1,505,705
+70,628
+5% +$206K
2021 Q3
4 quarters
VERA icon
43
Vera Therapeutics
VERA
$2B
$3.33M 0.29%
+156,129
New +$2.92M
2022 Q3
0 quarters
FATE icon
44
Fate Therapeutics
FATE
$218M
$3.17M 0.28%
141,558
-585,028
-81% -$16.9M
2018 Q4
15 quarters
PNT
45
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$3.17M 0.27%
+410,052
New +$3.48M
2022 Q3
0 quarters
A icon
46
Agilent Technologies
A
$48.7B
$2.62M 0.23%
21,521
+1,257
+6% +$161K
2020 Q4
7 quarters
TEVA icon
47
CALL
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$2.2M 0.19%
272,900
+180,000
+194% +$1.59M
2021 Q2
5 quarters
MASS icon
48
908 Devices
MASS
$479M
$2.15M 0.19%
130,768
-339,676
-72% -$6.6M
2022 Q1
2 quarters
AMN icon
49
PUT
AMN Healthcare
AMN
$1.56B
$2.01M 0.17%
+19,000
New +$2.08M
2022 Q3
0 quarters
ICLR icon
50
Icon
ICLR
$13.2B
$1.88M 0.16%
10,212
+4,625
+83% +$1.01M
2021 Q3
4 quarters
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Eversept Partners held 89 positions worth $1.15B, down 18% from $1.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners withdrew a net $97.3M in Q3 2022, closing 19 positions and reducing 25 holdings. Its most notable exit was AstraZeneca, an estimated $67.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 70% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Seres Therapeutics worth $12.4M.

  • Eversept Partners's largest Q3 2022 buy was Seres Therapeutics: 96,791 shares worth $12.4M.
  • Eversept Partners added most to GSK in Q3 2022, an estimated $63.1M increase.
  • Eversept Partners's biggest Q3 2022 reduction was Avantor, cutting an estimated $28M.
  • Eversept Partners fully exited AstraZeneca in Q3 2022, selling an estimated $67.4M.
  • Eversept Partners's ten largest holdings make up 66% of its $1.15B portfolio in Q3 2022.
  • Eversept Partners opened 12 new positions and closed 19 in Q3 2022.
  • Eversept Partners's portfolio value fell 18% quarter-over-quarter to $1.15B.

Based on Eversept Partners's 13F filing for Q3 2022, filed 14 Nov 2022.